Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Leche humana exclusiva en neonatos prematuros y factores de riesgo de envejecimiento vascular temprano (NEOVASC) (NEOVASC)

15 de septiembre de 2026 actualizado por: Ursula Kohlendorfer, Prolacta Bioscience

Efectos de una dieta exclusiva de leche humana en neonatos prematuros sobre los factores de riesgo de envejecimiento vascular temprano (NEOVASC)

Early vascular aging has its origins in fetal and neonatal life. The NEOVASC clinical trial aims to determine the effects of an exclusive human milk diet in extremely preterm infants on long-term cardiovascular health.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

Early vascular aging has its origins in fetal and neonatal life. This early period of life plays an important role in the development of obesity, high blood pressure, abnormalities in lipid metabolism and non-insulin dependent diabetes. Increased cardiovascular risk in formerly preterm infants constitutes a health problem of steadily growing relevance. Emerging evidence suggests that human milk feeding has substantial benefits to the health of all infants, especially for those born prematurely. Unfortunately, human milk alone does not provide sufficient concentrations of nutrients, especially calcium, phosphorus, protein, and fat needed for these infants to grow satisfactorily. For that purpose, fortifiers are used to help increase the nutritional value of human milk.

The NEOVASC study is a multicentric, prospective, randomized, controlled, open and parallel group clinical trial. A total of 200 extremely preterm infants and 100 term infants are recruited for the test and control group, respectively. Infants in the test group (i.e., premature neonates) are randomized to either:

  1. An exclusive human milk diet which contains mother's milk or pasteurized donor human milk and a human milk fortifier until 36 weeks of gestation; OR
  2. Human milk (as long as available) and a human milk fortifier (as long as human milk is available) until a maximum of 32 weeks of gestation and thereafter human milk with a bovine-based fortifier or preterm formula.

After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included. Participants within this control group are not enrolled at the time of birth but instead recruited in various kindergartens at the age of five. Therefore, data from birth is taken from the mother-child-booklet, which contains clinical records about the pregnancy, birth and early life of children born in Austria. The total study duration is scheduled for 96 months with a recruitment phase of 36 months. Follow-up visits are planned at one, two and five years of age for the test group.

The purpose of the NEOVASC clinical trial is to characterize early life stressors by assessing the effects of a physiological (i.e., human milk-based) nutrition in extremely preterm infants during the vulnerable preterm period on the risk of metabolic and vascular complications in later life. Outcomes include predictors and intermediate components of cardiovascular disease.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

200

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

    • Tyrol
      • Innsbruck, Tyrol, Austria, A-6020
        • Reclutamiento
        • Medical University of Innsbruck
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Christoph Binder, MD
        • Investigador principal:
          • Martin Wald, MD
        • Investigador principal:
          • Burkhard Simma, MD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

1 día a 5 años (Niño)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Preterm-born group:

Inclusion Criteria:

  1. Extremely preterm infants with a birth weight of 500-1250g.
  2. Feeding is NPO or exclusive human milk prior to enrollment.
  3. Parent(s) willing to sign informed consent.-

Exclusion Criteria:

  1. Infants with a birth weight <500g or >1250g
  2. Subjects diagnosed with inborn errors of metabolism such as galactosemia, phenylketonuria
  3. Subjects who have not been NPO or fed exclusive human milk diet prior to enrollment.
  4. Presence of major congenital malformation.
  5. Presence of intestinal perforation or Stage 2 Necrotizing enterocolitis prior to enrollment.
  6. Parent(s) not willing to sign informed consent.
  7. Unable to participate for any reason based on the decision of the study investigator (e.g. unlikely to survive the study period).

Term-born group:

Inclusion criteria

  1. Term-born children with an adequate birth weight
  2. Parent(s) willing to sign informed consent

Exclusion criteria

  1. Subjects with acute or chronic illness
  2. Parent(s) not willing to sign informed consent

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Randomized study product group

receiving study product (human milk fortifier "Humavant") until a gestational age of 36 weeks

Premature infants are randomized to either:

  1. An exclusive human milk diet which contains mother's milk or pasteurized donor human milk and the human milk fortifier until 36 weeks of gestation; OR
  2. Human milk (as long as available) and the human milk fortifier (as long as human milk is available) until a maximum of 32 weeks of gestation and thereafter human milk with a bovine-based fortifier or preterm formula.

After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included.

Comparador activo: Randomized control group

receiving study product until a gestational age of 32 weeks and reference product (bovine based fortifier or bovine formula) after 32 weeks of gestation

Premature infants are randomized to either:

  1. An exclusive human milk diet which contains mother's milk or pasteurized donor human milk and the human milk fortifier until 36 weeks of gestation; OR
  2. Human milk (as long as available) and the human milk fortifier (as long as human milk is available) until a maximum of 32 weeks of gestation and thereafter human milk with a bovine-based fortifier or preterm formula.

After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included.

Sin intervención: Term control group

Term-born controls as a reference group for outcome parameters

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Fasting blood glucose
Periodo de tiempo: "First day of life" up to "five years of life"

Primary outcome is the difference in fasting blood glucose at five years of age

"First day of life" up to "five years of life"
Blood pressure
Periodo de tiempo: "First day of life" up to "five years"

Primary outcome is the difference in blood pressure at five years of age

"First day of life" up to "five years"
Distensibility of aorta
Periodo de tiempo: "First day of life" up to "five years"

Primary outcome is the difference in the distensibility of the descending aorta using validated echocardiographic protocols at five years of age

"First day of life" up to "five years"

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Fasting blood glucose
Periodo de tiempo: "First day of life" up to "24 months"

Secondary outcome is fasting glucose at a corrected age of one and two years.

"First day of life" up to "24 months"
Blood pressure
Periodo de tiempo: "First day of life" up to "24 months"

Secondary outcome is blood pressure at a corrected age of one and two years.

"First day of life" up to "24 months"
BMI
Periodo de tiempo: "First day of life" up to "five years"

Secondary outcome is BMI at five years of age, weight in kilograms and height in meters will be combined to report BMI in kg/m2

"First day of life" up to "five years"
Insulin sensitivity
Periodo de tiempo: "First day of life" up to "five years"

Secondary outcome is insulin sensitivity at five years of age

"First day of life" up to "five years"
Lipid profile
Periodo de tiempo: "First day of life" up to "five years"

Secondary outcome is lipid profile at five years of age

"First day of life" up to "five years"

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Fasting blood glucose
Periodo de tiempo: "five years of age"

Difference in fasting blood glucose between preterm- and term-born children at five years of age

"five years of age"
Blood pressure
Periodo de tiempo: "five years of age"

Difference in blood pressure between preterm- and term-born children at five years of age

"five years of age"
Distensibility of the descending aorta
Periodo de tiempo: "five years of age"

Difference in the distensibility of the descending aorta between preterm- and term-born children using validated echocardiographic protocols at five years of age Results will be compared to results of term-born children

"five years of age"
BMI
Periodo de tiempo: "five years of age"

Difference in BMI between preterm- and term-born children at five years of age, weight in kilograms and height in meters will be combined to report BMI in kg/m2

"five years of age"
Insulin sensitivity
Periodo de tiempo: "five years of age"

Difference in insulin sensitivity between preterm- and term-born children at five years of age

"five years of age"
Lipid profile
Periodo de tiempo: "five years of age"

Difference in lipid profile between preterm- and term-born children at five years of age

"five years of age"

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Ursula Kiechl-Kohlendorfer, MD, MSc, Medical University Innsbruck

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

9 de octubre de 2020

Finalización primaria (Estimado)

1 de junio de 2028

Finalización del estudio (Estimado)

1 de junio de 2028

Fechas de registro del estudio

Enviado por primera vez

26 de mayo de 2020

Primero enviado que cumplió con los criterios de control de calidad

30 de mayo de 2020

Publicado por primera vez (Actual)

4 de junio de 2020

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

15 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • NEOVASC
  • 868624 (Otro número de subvención/financiamiento: Austrian Research Promotion Agency)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .